Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen’s BCMA-Targeting CAR-T, AstraZeneca’s Evusheld Among EU Verdict Hopefuls

Executive Summary

The EMA is poised to say whether or not six new drugs are on track for pan-EU approval, including Janssen’s first cell therapy and an antibody combination to prevent COVID-19 in people with poor immune response.

You may also be interested in...



Janssen’s Multiple Myeloma Gene Therapy On Track For EU-Wide Approval

The European Medicines Agency’s human medicines committee has recommended five new drugs for use in the EU at its latest monthly meeting.

Roche Seeks Speedy EU Review For Second Bispecific Antibody

The European Medicines Agency was this week deciding whether to grant accelerated assessment for glofitamab.

AstraZeneca’s Evusheld Wins EU Marketing Nod For Preventing COVID-19

The European Commission is expected to make a “rapid decision” on the European Medicines Agency’s recommendation today that Evusheld should be approved.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel